2. Кобалава Ж.Д., Котовская Ю.В., Старостина Е.Г., Виллевальде С.В. от имени исследователей АРГУС-2. Проблемы взаимодействия врача и пациента и контроль артериальной гипертонии в России. Основные результаты Российской научно-практической программы АРГУС-2. Кардиология. 2007; 47 (3): 38–47. / Kobalava Zh.D., Kotovskaia Iu. V., Starostina E.G., Villeval'de S.V. ot imeni issledovatelei ARGUS-2. Problemy vzaimodeistviia vracha i patsienta i kontrol' arterial'noi gipertonii v Rossii. Osnovnye rezul'taty Rossiiskoi nauchno-prak-ticheskoi programmy ARGUS-2. Kardiologiia. 2007; 47 (3): 38–47. [in Russian]
3. Лихачев С.А., Лущик А.В. Артериальная гипертензия и приверженность антигипертензивной терапии по данным популяционного исследования. Бюл. медицинских интернет-конференций. 2014; 4 (2): 103. / Likhachev S.A., Lushchik A.V. Arterial'naia gipertenziia i priverzhennost' antigipertenzivnoi terapii po dannym populiatsionnogo issledovaniia. Biul. meditsinskikh internet-konferentsii. 2014; 4 (2): 103. [in Russian]
4. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940–8. DOI: 10.1093/eurheartj/eht295
5. Национальные рекомендации Российского научного медицинского общества терапевтов по количественной оценке приверженности к лечению. М., 2017. / Natsional'nye rekomendatsii Rossiiskogo nauchnogo meditsinskogo obshchestva terapevtov po kolichestvennoi otsenke priverzhennosti k lecheniiu. M., 2017. [in Russian]
6. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database System Rev. The Cochrane Collaboration: John Wiley and Sons, Ltd. 2006. Issue 4. 
7. Sewitch MJ, Leffondre K, Dobkin PL. Clustering patients according to health perceptions: relationhips to psychosocial characteristics and medication nonadherence. J Psychosom Res 2004; 56: 323–32.
8. Остроумова О.Д., Кочетков А.И. Антигипертензивная и вазопротективная эффективность фиксированных комбинаций амлодипин/лизиноприл и бисопролол/гидрохлоротиазид. Consilium Medicum. 2016; 18 (12): 31–9. / Ostroumova O.D., Kochetkov A.I. Antihypertensive and target-organ protective effects of fixed-dose combinations of amlodipine/lisinopril and bisoprolol/hydrochlorothiazide.  Consilium Medicum. 2016; 18 (12): 31–9. [in Russian]
9. Hostalek U, Czarnecka D, Koch EMW. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. Cardiol Ther 2015; 4 (Issue 2): 179–90.
10. Чесникова А.И., Сафроненко В.А., Коломацкая О.Е. Оценка эффективности фиксированной комбинации бисопролола и амлодипина в амбулаторном лечении больных артериальной гипертензией и ишемической болезнью сердца. Кардиология. 2014; 9: 30–6. / Chesnikova A.I., Safronenko V.A., Kolomatskaia O.E. Otsenka effektivnosti fiksirovannoi kombinatsii bisoprolola i amlodipina v ambulatornom lechenii bol'nykh arterial'noi gipertenziei i ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2014; 9: 30–6. [in Russian]. 
11. Линчак Р.М., Шумилова К.М., Мартынюк А.Д. и др. Применение комбинированного препарата лозартана и гидрохлортиазида в антигипертензивной терапии. Рацион. фармакотерапия в кардиологии. 2006; 2 (1): 18–26. / Linchak R.M., Shumilova K.M., Martyniuk A.D. i dr. Primenenie kombinirovannogo preparata lozartana i gidrokhlortiazida v antigipertenzivnoi terapii. Ratsion. farmakoterapiia v kardiologii. 2006; 2 (1): 18–26. [in Russian] 
12. Линчак Р.М. Сравнительная эффективность фиксированной комбинации периндоприл/индапамид у больных артериальной гипертензией различного пола и возраста. Кардиология. 2010; 50 (6): 35–40. / Linchak R.M. Sravnitel'naia effektivnost' fiksirovannoi kombinatsii perindopril/indapamid u bol'nykh arterial'noi gipertenziei razlichnogo pola i vozrasta. Kardiologiia. 2010; 50 (6): 35–40. [in Russian]
13. Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л. и др. Первые результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III. Качественная клиническая практика. 2010; 1: 54–60. / Leonova M.V., Belousov D.Iu., Shteinberg L.L. i dr. Pervye rezul'taty farmakoepidemiologicheskogo issledovaniia arterial'noi gipertonii PIFAGOR III. Kachestvennaia klinicheskaia praktika. 2010; 1: 54–60. [in Russian]
14. Пономарева А.И., Кетова Г.Г., Компаниец О.Г. Клинико-фармакологические приоритеты в выборе блокаторов ренин-ангиотензиновой системы и диуретиков у пациентов с неосложненной гипертонической болезнью. Системные гипертензии. 2017; 14 (2): 75–79. DOI: 10.26442/2075-082X_14.2.75-79. / Ponomareva A.I., Ketova G.G., Kompaniets O.G. Clinical-pharmacological priorities in the election of blockators of the renin-angiotenzine system and diuretics in patients with uncompleted hypertension. Systemic Hypertension. 2017; 14 (2): 75–79. DOI: 10.26442/2075-082X_14.2.75-79 [in Russian]
15. Государственный реестр лекарственных средств МЗ РФ // http:www.grls.rosminzdrav.ru / Gosudarstvennyi reestr lekarstvennykh sredstv MZ RF // http:www.grls.rosminzdrav.ru [in Russian]
16. De la Sierra A et al. Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. J Clin Hypertens 2015; 17 (11): 857–65.
17. McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. Drugs 2002; 62 (18): 2677–96.
18. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426–35.
19. Рекомендации ESC по лечению пациентов с желудочковыми нарушениями ритма и профилактике внезапной сердечной смерти 2015. Рос. кардиол. журн. 2016; 7 (135): 5–86. http://dx.doi.org/10.15829/1560-4071-2016-7-5-86 / Rekomendatsii ESC po lecheniiu patsientov s zheludochkovymi narusheniiami ritma i profilaktike vnezapnoi serdechnoi smerti 2015. Ros. kardiol. zhurn. 2016; 7 (135): 5–86. http://dx.doi.org/10.15829/ 1560-4071-2016-7-5-86 [in Russian]
20. Аверьянов А.В., Адрианов А.В., Ардашев А.В. и др. Внезапная сердечная смерть. Под ред. Е.В.Шляхто, Г.П.Арутюнова, Ю.Н.Беленкова, А.В.Ардашева. М.: Медпрактика-М, 2015. / Aver'ianov A.V., Adrianov A.V., Ardashev A.V. i dr. Vnezapnaia serdechnaia smert'. Pod red. E.V.Shliakhto, G.P.Arutiunova, Iu.N.Belenkova, A.V.Ardasheva. M.: Medpraktika-M, 2015. [in Russian]
21. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31: 143–7.
22. Lin ZP, Dong M, Liu J. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. Eur Rev Med Pharmacol Sci 2013; 17 (6): 794–801.
23. Ferguson JD, Ormerod O, Lenox-Smith AJ. Bisoprolol alone and in combination with amlodipine ore nifedipine in the treatment of chronic stable angina. Int J Сlin Pract 2000; 54 (6): 360–3.
24. Кириченко А.А. Бисопролол в практике терапевта. РМЖ. 2015; 27: 1594–7. / Kirichenko A.A. Bisoprolol v praktike terapevta. RMZh. 2015; 27: 1594–7. [in Russian]
25. Лупанов В.П. Влияние кардиоселективного бета-блокатора бисопролол на предупреждение эффектов бета-адренергической стимуляции и препятствие реализации кардиотоксического влияния катехоламинов при лечении больных с ССЗ. Мед. совет. 2016; 13. / Lupanov V.P. Vliianie kardioselektivnogo beta-blokatora bisoprolol na preduprezhdenie effektov beta-adrenergicheskoi stimuliatsii i prepiatstvie realizatsii kardiotoksicheskogo vliianiia katekholaminov pri lechenii bol'nykh s SSZ. Med. sovet. 2016; 13. [in Russian]
26. Zhang H et al. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation 2015; 131: 2194–201.
27. Raposeiras-Roubin S et al. Beta-blocker Use After an Acute Coronary Syndrome. Which one, in Whom, and for How Long. Rev Esp Cardiol 2015; 68 (7): 585–91.
28. Law MR et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2009; 338: b1665.
29. Мазур Н.А. Оптимальная медикаментозная терапия больных стенокардией и ее влияние на смертность. РМЖ. 2017; 25 (14): 1067–72. / Mazur N.A. Optimal'naia medikamentoznaia terapiia bol'nykh stenokardiei i ee vliianie na smertnost'. RMZh. 2017; 25 (14): 1067–72. [in Russian]
30. CIBIS II. Lancet 1999; 353: 9–13. 
31. Затейщикова А.А. Бисопролол в лечении сердечной недостаточности. РМЖ. 2015; 15: 874–6. / Zateishchikova A.A. Bisoprolol v lechenii serdechnoi nedostatochnosti. RMZh. 2015; 15: 874–6. [in Russian]
32. Kotseva K et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23 (6): 636–48.
33. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015; 12 (1):19–25. / Leonova M.V., Shteinberg L.L., Belousov Yu.B. Pharmacoepidemiology of arterial hypertension in Russia: the analysis of physicians acceptance (according to the results of PIFAGOR IV). Systemic Hypertension. 2015; 12 (1): 19–25. [in Russian]]
34. WHO Model List of Essential Medicines. April 2015. 19th edition, in the core list of essential medicines selecting the most efficacious, safe and cost-effective medicines.
35. Bertrand ME et al. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis 2009; 102: 89–96.
36. Bertrand ME et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J 2015; 170: 1092–8.
37. Tsoukas G et al. CONFIDENCE Investigators. Am J Cardiovasc Drugs 2011; 11 (1): 45–55.
38. Brugts JJ, Bertrand M, Remme W et al. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. Cardiovasc Drugs Ther 2017; 31: 391–400. DOI: 10/1007/s10557-017-6747-9

________________________________________________

1. Kobalava Zh.D., Villeval'de S.V., Isikova Kh. V. Povyshenie priverzhennosti i motivatsii k antigipertenzivnoi terapii u bol'nykh arterial'noi gipertoniei s pomoshch'iu obrazovatel'nykh programm i ratsional'nogo primeneniia ingibitora angiotenzinprevrashchaiushchego fermenta perindoprila. Rezul'taty issledovaniia PRIZMA. Kardiologiia. 2010; 50 (11): 17–26. [in Russian]
2. Kobalava Zh.D., Kotovskaia Iu. V., Starostina E.G., Villeval'de S.V. ot imeni issledovatelei ARGUS-2. Problemy vzaimodeistviia vracha i patsienta i kontrol' arterial'noi gipertonii v Rossii. Osnovnye rezul'taty Rossiiskoi nauchno-prak-ticheskoi programmy ARGUS-2. Kardiologiia. 2007; 47 (3): 38–47. [in Russian]
3. Likhachev S.A., Lushchik A.V. Arterial'naia gipertenziia i priverzhennost' antigipertenzivnoi terapii po dannym populiatsionnogo issledovaniia. Biul. meditsinskikh internet-konferentsii. 2014; 4 (2): 103. [in Russian]
4. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940–8. DOI: 10.1093/eurheartj/eht295
5. Natsional'nye rekomendatsii Rossiiskogo nauchnogo meditsinskogo obshchestva terapevtov po kolichestvennoi otsenke priverzhennosti k lecheniiu. M., 2017. [in Russian]
6. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database System Rev. The Cochrane Collaboration: John Wiley and Sons, Ltd. 2006. Issue 4. 
7. Sewitch MJ, Leffondre K, Dobkin PL. Clustering patients according to health perceptions: relationhips to psychosocial characteristics and medication nonadherence. J Psychosom Res 2004; 56: 323–32.
8. Ostroumova O.D., Kochetkov A.I. Antihypertensive and target-organ protective effects of fixed-dose combinations of amlodipine/lisinopril and bisoprolol/hydrochlorothiazide.  Consilium Medicum. 2016; 18 (12): 31–9. [in Russian]
9. Hostalek U, Czarnecka D, Koch EMW. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. Cardiol Ther 2015; 4 (Issue 2): 179–90.
10. Chesnikova A.I., Safronenko V.A., Kolomatskaia O.E. Otsenka effektivnosti fiksirovannoi kombinatsii bisoprolola i amlodipina v ambulatornom lechenii bol'nykh arterial'noi gipertenziei i ishemicheskoi bolezn'iu serdtsa. Kardiologiia. 2014; 9: 30–6. [in Russian]. 
11. Linchak R.M., Shumilova K.M., Martyniuk A.D. i dr. Primenenie kombinirovannogo preparata lozartana i gidrokhlortiazida v antigipertenzivnoi terapii. Ratsion. farmakoterapiia v kardiologii. 2006; 2 (1): 18–26. [in Russian] 
12. Linchak R.M. Sravnitel'naia effektivnost' fiksirovannoi kombinatsii perindopril/indapamid u bol'nykh arterial'noi gipertenziei razlichnogo pola i vozrasta. Kardiologiia. 2010; 50 (6): 35–40. [in Russian]
13. Leonova M.V., Belousov D.Iu., Shteinberg L.L. i dr. Pervye rezul'taty farmakoepidemiologicheskogo issledovaniia arterial'noi gipertonii PIFAGOR III. Kachestvennaia klinicheskaia praktika. 2010; 1: 54–60. [in Russian]
14. Ponomareva A.I., Ketova G.G., Kompaniets O.G. Clinical-pharmacological priorities in the election of blockators of the renin-angiotenzine system and diuretics in patients with uncompleted hypertension. Systemic Hypertension. 2017; 14 (2): 75–79. DOI: 10.26442/2075-082X_14.2.75-79 [in Russian]
15. Gosudarstvennyi reestr lekarstvennykh sredstv MZ RF // http:www.grls.rosminzdrav.ru [in Russian]
16. De la Sierra A et al. Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. J Clin Hypertens 2015; 17 (11): 857–65.
17. McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. Drugs 2002; 62 (18): 2677–96.
18. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426–35.
19. Rekomendatsii ESC po lecheniiu patsientov s zheludochkovymi narusheniiami ritma i profilaktike vnezapnoi serdechnoi smerti 2015. Ros. kardiol. zhurn. 2016; 7 (135): 5–86. http://dx.doi.org/10.15829/ 1560-4071-2016-7-5-86 [in Russian]
20. Aver'ianov A.V., Adrianov A.V., Ardashev A.V. i dr. Vnezapnaia serdechnaia smert'. Pod red. E.V.Shliakhto, G.P.Arutiunova, Iu.N.Belenkova, A.V.Ardasheva. M.: Medpraktika-M, 2015. [in Russian]
21. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31: 143–7.
22. Lin ZP, Dong M, Liu J. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. Eur Rev Med Pharmacol Sci 2013; 17 (6): 794–801.
23. Ferguson JD, Ormerod O, Lenox-Smith AJ. Bisoprolol alone and in combination with amlodipine ore nifedipine in the treatment of chronic stable angina. Int J Сlin Pract 2000; 54 (6): 360–3.
24. Kirichenko A.A. Bisoprolol v praktike terapevta. RMZh. 2015; 27: 1594–7. [in Russian]
25. Lupanov V.P. Vliianie kardioselektivnogo beta-blokatora bisoprolol na preduprezhdenie effektov beta-adrenergicheskoi stimuliatsii i prepiatstvie realizatsii kardiotoksicheskogo vliianiia katekholaminov pri lechenii bol'nykh s SSZ. Med. sovet. 2016; 13. [in Russian]
26. Zhang H et al. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation 2015; 131: 2194–201.
27. Raposeiras-Roubin S et al. Beta-blocker Use After an Acute Coronary Syndrome. Which one, in Whom, and for How Long. Rev Esp Cardiol 2015; 68 (7): 585–91.
28. Law MR et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2009; 338: b1665.
29. Mazur N.A. Optimal'naia medikamentoznaia terapiia bol'nykh stenokardiei i ee vliianie na smertnost'. RMZh. 2017; 25 (14): 1067–72. [in Russian]
30. CIBIS II. Lancet 1999; 353: 9–13. 
31. Zateishchikova A.A. Bisoprolol v lechenii serdechnoi nedostatochnosti. RMZh. 2015; 15: 874–6. [in Russian]
32. Kotseva K et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23 (6): 636–48.
33. Leonova M.V., Shteinberg L.L., Belousov Yu.B. Pharmacoepidemiology of arterial hypertension in Russia: the analysis of physicians acceptance (according to the results of PIFAGOR IV). Systemic Hypertension. 2015; 12 (1): 19–25. [in Russian]
34. WHO Model List of Essential Medicines. April 2015. 19th edition, in the core list of essential medicines selecting the most efficacious, safe and cost-effective medicines.
35. Bertrand ME et al. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis 2009; 102: 89–96.
36. Bertrand ME et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J 2015; 170: 1092–8.
37. Tsoukas G et al. CONFIDENCE Investigators. Am J Cardiovasc Drugs 2011; 11 (1): 45–55.
38. Brugts JJ, Bertrand M, Remme W et al. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. Cardiovasc Drugs Ther 2017; 31: 391–400. DOI: 10/1007/s10557-017-6747-9

Е.Д.Космачева1,2, О.Г.Компаниец*1, Н.А.Зубарева1,2

1 ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России. 350063, Россия, Краснодар, ул. Седина, д. 4;
2 ГБУЗ «НИИ – Краевая клиническая больница №1 им. проф. С.В.Очаповского» Минздрава Краснодарского края. 350029, Россия, Краснодар,  ул. 1 Мая, д. 16
*olga-kompaniets1@yandex.ru

________________________________________________